Shares of ImmuCell Co. (NASDAQ:ICCC – Get Free Report) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $5.12 and traded as low as $4.56. ImmuCell shares last traded at $4.62, with a volume of 22,230 shares trading hands.
ImmuCell Price Performance
The stock’s fifty day simple moving average is $5.10 and its 200-day simple moving average is $5.12. The company has a market capitalization of $35.79 million, a P/E ratio of -5.63 and a beta of 0.64. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.59 and a quick ratio of 0.81.
ImmuCell (NASDAQ:ICCC – Get Free Report) last released its quarterly earnings results on Monday, November 13th. The biotechnology company reported ($0.12) EPS for the quarter. The company had revenue of $5.40 million for the quarter. ImmuCell had a negative net margin of 38.70% and a negative return on equity of 22.63%.
Hedge Funds Weigh In On ImmuCell
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E.
- Five stocks we like better than ImmuCell
- How to Find Cloud Software Company Stocks to Trade and Invest
- The most upgraded stocks in November have two things in common
- Large Cap Stock Definition and How to Invest
- Monday.com rocked earnings like it’s the weekend
- Are Stock Buybacks Good for the Average Investor?
- Plan to own one retailer? Make it this one
Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.